Insulet Beats Sales and EPS Estimates Despite Slightly Lowering 2026 Outlook

Insulet beat Q2 2026 estimates on both revenue and profit, reporting sales of $801.7 million against a $787.4 million analyst forecast, up 23.5% year over year from $649.1 million. Adjusted EPS jumped 41.5% to $1.66, a 21-cent beat over the $1.45 consensus estimate, while GAAP net income came in at $95.0 million, or $1.37 per diluted share.

Despite the beat, Insulet lowered its full-year 2026 growth outlook, citing weaker-than-expected retention and utilization among type 2 diabetes patients, particularly in the first 90 days of therapy. Full-year constant-currency revenue growth is now guided to 20%-22% company-wide, down from a prior estimate of about 23%, with U.S. Omnipod growth cut to 17%-19%.

The stock fell on the news as investors focused on the trimmed outlook rather than the quarterly beat. Insulet still expects adjusted EPS to grow at least 30% for the year, with roughly 100 basis points of operating margin expansion, and now projects full-year adjusted EPS above $6.46, ahead of the $6.43 consensus.

The reaction highlights how sensitive Insulet's stock has become to Omnipod adoption trends beyond the type 1 diabetes base it built its business on. Investors will be watching upcoming quarters for signs that type 2 patient retention stabilizes, since that segment is central to the company's next leg of growth.

Related Stocks

• PODD
• FDS